Trial Meloxicam First
For a 36-year-old man with two weeks of right-sided back pain and paraspinal tenderness, trial meloxicam (an NSAID) as first-line therapy. This represents acute low back pain (duration <4 weeks), and NSAIDs are the evidence-based first-line pharmacologic treatment 1.
Rationale for NSAIDs as First-Line
The 2017 American College of Physicians systematic review establishes NSAIDs as first-line pharmacologic therapy for low back pain 1. While this guideline found that NSAIDs provide "small to moderate, primarily short-term effects on pain," they remain the standard of care with the strongest evidence base. Meloxicam specifically has demonstrated efficacy in acute back pain syndromes—a 2001 randomized controlled trial showed both 7.5 mg and 15 mg doses significantly improved pain compared to placebo in acute sciatica, with similar efficacy to diclofenac 150 mg 2.
Start with meloxicam 7.5-15 mg daily for 7-14 days 2, 3. The step-wise approach commonly used involves starting with oral dosing, though injectable forms can be considered for more severe presentations 3.
Why Not Lidoderm Patch
Lidoderm (lidocaine patch) is FDA-approved specifically for post-herpetic neuralgia, not acute musculoskeletal back pain 4. The clinical trials supporting its use were conducted exclusively in neuropathic pain patients with post-herpetic neuralgia 4. There is no evidence base for its use in acute mechanical back pain with paraspinal tenderness. This represents an off-label use without supporting data for this indication.
Why Not TENS as First-Line
While TENS may provide modest adjunctive benefit, it should not be first-line monotherapy. A 2026 pilot study in emergency department patients with acute back pain showed TENS plus standard care reduced pain scores by only 1.4-1.7 points on a 10-point scale—statistically significant but not meeting clinical significance thresholds 5. The WFNS Spine Committee recommendations position TENS as an adjunct to improve acute low back pain, not as primary therapy 6. A 2009 guideline review explicitly recommends against referring for TENS as a primary modality 7.
Clinical Algorithm
- Initiate meloxicam 7.5-15 mg daily for 7-14 days
- Advise continued activity within pain limits—avoid bed rest 6, 7
- Reassure that 90% of acute episodes resolve within 6 weeks 7
- Consider adjunctive measures if inadequate response:
- Ice application to painful areas
- Gentle stretching exercises
- TENS may be added as adjunct (not replacement) 6
Important Caveats
- Screen for red flags before assuming benign mechanical pain: fever, unexplained weight loss, history of cancer, severe progressive neurologic deficits, bowel/bladder dysfunction, or trauma suggesting fracture
- Assess cardiovascular and GI risk before prescribing NSAIDs—meloxicam has preferential COX-2 selectivity but still carries standard NSAID risks 1
- If no improvement after 1-2 weeks, consider referral for goal-directed manual physical therapy 7
- Imaging is not indicated unless no improvement after 6 weeks or red flags present 7
The evidence clearly supports NSAIDs like meloxicam as first-line therapy, with TENS reserved as adjunctive treatment and lidocaine patches lacking any evidence for this indication.